Wall Street analysts expect Oxford Immunotec Global PLC (NASDAQ:OXFD) to report $30.11 million in sales for the current quarter, according to Zacks. Three analysts have made estimates for Oxford Immunotec Global PLC’s earnings, with the lowest sales estimate coming in at $30.00 million and the highest estimate coming in at $30.29 million. Oxford Immunotec Global PLC posted sales of $26.11 million in the same quarter last year, which would indicate a positive year over year growth rate of 15.3%. The business is expected to announce its next earnings report on Tuesday, November 7th.

According to Zacks, analysts expect that Oxford Immunotec Global PLC will report full year sales of $30.11 million for the current fiscal year, with estimates ranging from $104.47 million to $105.20 million. For the next year, analysts anticipate that the firm will report sales of $122.67 million per share, with estimates ranging from $120.43 million to $124.20 million. Zacks’ sales averages are a mean average based on a survey of research firms that that provide coverage for Oxford Immunotec Global PLC.

Oxford Immunotec Global PLC (NASDAQ:OXFD) last posted its quarterly earnings results on Tuesday, August 1st. The company reported ($0.32) earnings per share for the quarter, hitting the Thomson Reuters’ consensus estimate of ($0.32). Oxford Immunotec Global PLC had a negative return on equity of 35.76% and a negative net margin of 34.58%. The firm had revenue of $26.10 million during the quarter, compared to analysts’ expectations of $25.05 million. During the same quarter in the previous year, the business earned ($0.29) earnings per share. The company’s revenue was up 35.9% on a year-over-year basis.

A number of equities analysts recently issued reports on OXFD shares. Cowen and Company restated a “buy” rating and issued a $22.00 target price on shares of Oxford Immunotec Global PLC in a research note on Thursday, August 3rd. Piper Jaffray Companies restated a “buy” rating and issued a $26.00 target price on shares of Oxford Immunotec Global PLC in a research note on Thursday, August 3rd. BTIG Research started coverage on Oxford Immunotec Global PLC in a research note on Thursday, September 28th. They issued a “buy” rating and a $21.00 target price for the company. Finally, Zacks Investment Research upgraded Oxford Immunotec Global PLC from a “sell” rating to a “hold” rating in a research note on Wednesday. One analyst has rated the stock with a sell rating, two have given a hold rating and three have issued a buy rating to the stock. Oxford Immunotec Global PLC presently has an average rating of “Hold” and an average target price of $22.00.

ILLEGAL ACTIVITY NOTICE: This piece was first posted by American Banking News and is the sole property of of American Banking News. If you are viewing this piece on another domain, it was illegally stolen and reposted in violation of US & international copyright legislation. The original version of this piece can be accessed at https://www.americanbankingnews.com/2017/10/06/analysts-anticipate-oxford-immunotec-global-plc-oxfd-will-announce-quarterly-sales-of-30-11-million.html.

Shares of Oxford Immunotec Global PLC (OXFD) opened at 16.87 on Friday. The stock’s market cap is $389.29 million. Oxford Immunotec Global PLC has a 52-week low of $11.88 and a 52-week high of $19.51. The company’s 50-day moving average price is $15.80 and its 200-day moving average price is $15.64.

In related news, Director Richard A. Sandberg sold 3,000 shares of the firm’s stock in a transaction on Friday, September 1st. The stock was sold at an average price of $15.82, for a total value of $47,460.00. Following the completion of the transaction, the director now owns 18,000 shares in the company, valued at approximately $284,760. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Peter Wrighton-Smith sold 55,000 shares of the firm’s stock in a transaction on Monday, October 2nd. The stock was sold at an average price of $16.78, for a total value of $922,900.00. The disclosure for this sale can be found here. Insiders sold a total of 90,110 shares of company stock valued at $1,523,514 in the last 90 days. 8.11% of the stock is currently owned by company insiders.

Hedge funds have recently modified their holdings of the stock. American International Group Inc. raised its stake in Oxford Immunotec Global PLC by 7.1% in the 1st quarter. American International Group Inc. now owns 13,668 shares of the company’s stock worth $212,000 after acquiring an additional 904 shares during the last quarter. Nationwide Fund Advisors raised its stake in Oxford Immunotec Global PLC by 1.9% in the 1st quarter. Nationwide Fund Advisors now owns 13,765 shares of the company’s stock worth $213,000 after acquiring an additional 254 shares during the last quarter. Parkwood LLC raised its stake in Oxford Immunotec Global PLC by 12.9% in the 2nd quarter. Parkwood LLC now owns 12,799 shares of the company’s stock worth $215,000 after acquiring an additional 1,465 shares during the last quarter. Voya Investment Management LLC raised its stake in Oxford Immunotec Global PLC by 16.0% in the 2nd quarter. Voya Investment Management LLC now owns 13,345 shares of the company’s stock worth $224,000 after acquiring an additional 1,845 shares during the last quarter. Finally, Alliancebernstein L.P. purchased a new position in Oxford Immunotec Global PLC in the 2nd quarter worth $247,000. Institutional investors own 79.21% of the company’s stock.

Oxford Immunotec Global PLC Company Profile

Oxford Immunotec Global PLC is a diagnostics company. The Company is focused on developing and commercializing tests for under-served immune-regulated conditions. The Company’s product lines and development activities principally focus on four areas: infectious diseases, transplantation, autoimmune and inflammatory disease and immune-oncology.

Get a free copy of the Zacks research report on Oxford Immunotec Global PLC (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Oxford Immunotec Global PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global PLC and related companies with MarketBeat.com's FREE daily email newsletter.